| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
|
J Clin Oncol
|
2008
|
2.88
|
|
2
|
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
|
Proc Natl Acad Sci U S A
|
2013
|
2.47
|
|
3
|
NY-ESO-1: review of an immunogenic tumor antigen.
|
Adv Cancer Res
|
2006
|
2.44
|
|
4
|
Acetylation of Stat1 modulates NF-kappaB activity.
|
Genes Dev
|
2006
|
2.10
|
|
5
|
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
|
Proc Natl Acad Sci U S A
|
2003
|
2.09
|
|
6
|
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
|
J Clin Oncol
|
2011
|
2.08
|
|
7
|
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
|
Proc Natl Acad Sci U S A
|
2012
|
1.51
|
|
8
|
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets.
|
Cancer Res
|
2002
|
1.46
|
|
9
|
Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.
|
J Immunol
|
2006
|
1.43
|
|
10
|
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
|
J Clin Invest
|
2006
|
1.41
|
|
11
|
Marathon run under chemotherapy: is it possible?
|
Onkologie
|
2011
|
1.40
|
|
12
|
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
|
Blood
|
2005
|
1.38
|
|
13
|
Identification of cancer/testis genes by database mining and mRNA expression analysis.
|
Int J Cancer
|
2002
|
1.31
|
|
14
|
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
|
Cancer Immun
|
2007
|
1.28
|
|
15
|
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
|
Leuk Res
|
2010
|
1.25
|
|
16
|
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.17
|
|
17
|
Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs.
|
J Immunol
|
2003
|
1.11
|
|
18
|
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
|
Proc Natl Acad Sci U S A
|
2002
|
1.11
|
|
19
|
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
|
Int J Cancer
|
2010
|
1.11
|
|
20
|
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1.
|
J Immunother
|
2005
|
1.10
|
|
21
|
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
|
Cancer Immun
|
2003
|
1.08
|
|
22
|
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2.
|
Breast Cancer Res Treat
|
2003
|
1.05
|
|
23
|
Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
|
Cancer Res
|
2005
|
1.03
|
|
24
|
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
|
Gastric Cancer
|
2007
|
1.01
|
|
25
|
Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.
|
Clin Cancer Res
|
2010
|
1.00
|
|
26
|
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer.
|
BMC Cancer
|
2012
|
0.98
|
|
27
|
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.
|
Breast Cancer Res
|
2005
|
0.98
|
|
28
|
Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.
|
Cancer Immun
|
2002
|
0.97
|
|
29
|
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
|
Cancer
|
2007
|
0.94
|
|
30
|
Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC.
|
J Immunol Methods
|
2003
|
0.94
|
|
31
|
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
|
Int J Cancer
|
2011
|
0.94
|
|
32
|
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
|
Eur J Cancer
|
2012
|
0.91
|
|
33
|
Osteonecrosis of the jaw related to sunitinib.
|
Oral Maxillofac Surg
|
2011
|
0.91
|
|
34
|
DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
|
Clin Cancer Res
|
2008
|
0.90
|
|
35
|
Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
|
Cancer Immun
|
2004
|
0.89
|
|
36
|
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.
|
Cancer Immun
|
2005
|
0.88
|
|
37
|
Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer.
|
Oncology
|
2011
|
0.88
|
|
38
|
Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination.
|
Int J Cancer
|
2007
|
0.86
|
|
39
|
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.
|
Clin Cancer Res
|
2013
|
0.86
|
|
40
|
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
|
Onkologie
|
2007
|
0.84
|
|
41
|
Tumor antigen-specific T-cells are Present in the CD8alphaalpha+ T-cell effector-memory pool.
|
J Immunother
|
2008
|
0.83
|
|
42
|
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
|
Int J Cancer
|
2007
|
0.83
|
|
43
|
The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.
|
Int J Cancer
|
2013
|
0.83
|
|
44
|
Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
|
Am J Clin Oncol
|
2009
|
0.83
|
|
45
|
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.
|
Blood
|
2007
|
0.83
|
|
46
|
Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.
|
Cancer Immun
|
2003
|
0.82
|
|
47
|
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
|
Leuk Lymphoma
|
2010
|
0.82
|
|
48
|
Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy".
|
Cancer Res
|
2009
|
0.82
|
|
49
|
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
|
Cancer Immun
|
2013
|
0.82
|
|
50
|
Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
|
Clin Cancer Res
|
2008
|
0.82
|
|
51
|
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity.
|
Clin Cancer Res
|
2012
|
0.81
|
|
52
|
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.
|
Cancer Med
|
2013
|
0.80
|
|
53
|
Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.
|
Cancer Immunol Immunother
|
2008
|
0.80
|
|
54
|
Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
|
Int J Cancer
|
2002
|
0.79
|
|
55
|
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
|
Cancer Immun
|
2004
|
0.79
|
|
56
|
Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies.
|
Cancer Res
|
2012
|
0.79
|
|
57
|
Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer.
|
Oncol Res Treat
|
2014
|
0.78
|
|
58
|
Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
|
Int J Cancer
|
2006
|
0.78
|
|
59
|
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
|
Gynecol Oncol
|
2008
|
0.77
|
|
60
|
Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
|
Onkologie
|
2012
|
0.77
|
|
61
|
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
|
J Cardiovasc Pharmacol
|
2013
|
0.76
|
|
62
|
Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report.
|
Onkologie
|
2011
|
0.75
|
|
63
|
Chemotherapy for advanced gastric cancer.
|
J Clin Oncol
|
2007
|
0.75
|
|
64
|
Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.
|
Cancer Immunol Res
|
2014
|
0.75
|
|
65
|
Influence of a six month endurance exercise program on the immune function of prostate cancer patients undergoing Antiandrogen- or Chemotherapy: design and rationale of the ProImmun study.
|
BMC Cancer
|
2013
|
0.75
|
|
66
|
Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
|
Onkologie
|
2007
|
0.75
|
|
67
|
A multiplex method for the detection of serum antibodies against in silico-predicted tumor antigens.
|
Cancer Immunol Immunother
|
2014
|
0.75
|
|
68
|
[Adjuvant therapies in oncology: A critical benefit-risk assessment].
|
Onkologie
|
2011
|
0.75
|
|
69
|
[Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy].
|
Med Klin (Munich)
|
2010
|
0.75
|
|
70
|
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
|
Anticancer Drugs
|
2004
|
0.75
|
|
71
|
Urine antibody against human cancer antigen NY-ESO-1.
|
Cancer Immun
|
2002
|
0.75
|